Tumor blood vessels, a difficult hurdle for infiltrating leukocytes

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1776, Issue 2, 2007, Pages 160-174

  Castermans, Karolien ^a   Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cancer; Endothelial cell; Infiltration; Inflammation; Interaction; Leukocyte

Indexed keywords

ADDRESSIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD51 ANTIGEN; CD99 ANTIGEN; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GALECTIN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; LIPOSOME; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NERVE CELL ADHESION MOLECULE; PADGEM PROTEIN; VASCULAR ADHESION PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL INFILTRATION; CELL MIGRATION; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; LEUKOCYTE; MACROPHAGE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T LYMPHOCYTE; TREATMENT INDICATION; TUMOR IMMUNITY; VASCULAR TUMOR;

BIOLOGICAL MARKERS; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; LEUKOCYTE ROLLING; LEUKOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, BIOLOGICAL; NEOPLASMS; TUMOR ESCAPE;

EID: 36048982445     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2007.07.005     Document Type: Review

References (240)

1. Jaffee E.M. Immunotherapy of cancer. Ann. N.Y. Acad. Sci. 886 (1999) 67-72
2. Rosenberg S.A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350 14 (2004) 1461-1463
3. Mitchell M.S. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. 3 8 (2003) 1051-1059
4. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2 4 (2002) 227-238
5. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 2 (1994) 301-314
6. Shimizu Y., et al. Lymphocyte interactions with endothelial cells. Immunol. Today 13 3 (1992) 106-112
7. Kunkel E.J., et al. Absence of trauma-induced leukocyte rolling in mice deficient in both P-selectin and intercellular adhesion molecule 1. J. Exp. Med. 183 1 (1996) 57-65
8. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11 (1993) 767-804
9. Tanaka T., et al. Molecular determinants controlling homeostatic recirculation and tissue-specific trafficking of lymphocytes. Int. Arch. Allergy Immunol. 134 2 (2004) 120-134
10. Bonder C.S., et al. Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for alpha-4 integrin and vascular adhesion protein-1. Immunity 23 2 (2005) 153-163
11. Kurkijarvi R., et al. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur. J. Immunol. 31 10 (2001) 2876-2884
12. Salmi M., Hellman J., and Jalkanen S. The role of two distinct endothelial molecules, vascular adhesion protein-1 and peripheral lymph node addressin, in the binding of lymphocyte subsets to human lymph nodes. J. Immunol. 160 11 (1998) 5629-5636
13. Salmi M., et al. A mouse molecular mimic of human vascular adhesion protein-1. Mol. Immunol. 34 16-17 (1997) 1227-1236
14. Tohka S., et al. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo. FASEB J. 15 2 (2001) 373-382
15. Alon R., et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J. Cell Biol. 128 6 (1995) 1243-1253
16. Berlin C., et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80 3 (1995) 413-422
17. Mohamadzadeh M., et al. Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J. Clin. Invest 101 1 (1998) 97-108
18. Johnston B., and Butcher E.C. Chemokines in rapid leukocyte adhesion triggering and migration. Semin. Immunol. 14 2 (2002) 83-92
19. McIntyre T.M., et al. Cell-cell interactions: leukocyte-endothelial interactions. Curr. Opin. Hematol. 10 2 (2003) 150-158
20. Schleiffenbaum B., and Fehr J. Regulation and selectivity of leukocyte emigration. J. Lab. Clin. Med. 127 2 (1996) 151-168
21. Greenwood J., Wang Y., and Calder V.L. Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off. Immunology 86 3 (1995) 408-415
22. Staunton D.E., et al. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 52 6 (1988) 925-933
23. Rothlein R., et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 137 4 (1986) 1270-1274
24. Carlos T.M., and Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 84 7 (1994) 2068-2101
25. Chiba R., et al. Ligation of CD31 (PECAM-1) on endothelial cells increases adhesive function of alphavbeta3 integrin and enhances beta1 integrin-mediated adhesion of eosinophils to endothelial cells. Blood 94 4 (1999) 1319-1329
26. Ebeling O., et al. L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin. Eur. J. Immunol. 26 10 (1996) 2508-2516
27. Hubbe M., et al. L1 adhesion molecule on mouse leukocytes: regulation and involvement in endothelial cell binding. Eur. J. Immunol. 23 11 (1993) 2927-2931
28. Ruppert M., et al. The L1 adhesion molecule is a cellular ligand for VLA-5. J. Cell Biol. 131 6 Pt 2 (1995) 1881-1891
29. Oleszewski M., et al. Integrin and neurocan binding to L1 involves distinct Ig domains. J. Biol. Chem. 274 35 (1999) 24602-24610
30. Brummer J., et al. cis Interaction of the cell adhesion molecule CEACAM1 with integrin beta(3). Am. J. Pathol. 159 2 (2001) 537-546
31. Ebrahimnejad A., et al. Cell adhesion molecule CEACAM1 associates with paxillin in granulocytes and epithelial and endothelial cells. Exp. Cell Res. 260 2 (2000) 365-373
32. Irjala H., et al. The same endothelial receptor controls lymphocyte traffic both in vascular and lymphatic vessels. Eur. J. Immunol. 33 3 (2003) 815-824
33. Piali L., et al. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J. Cell Biol. 130 2 (1995) 451-460
34. Dumic J., Dabelic S., and Flogel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 1760 4 (2006) 616-635
35. Sato S., et al. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J. Immunol. 168 4 (2002) 1813-1822
36. Imaizumi T., et al. Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J. Leukoc. Biol. 72 3 (2002) 486-491
37. Matsumoto R., et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 273 27 (1998) 16976-16984
38. Feng D., et al. Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J. Exp. Med. 187 6 (1998) 903-915
39. Cook-Mills J.M., and Deem T.L. Active participation of endothelial cells in inflammation. J. Leukoc. Biol. 77 4 (2005) 487-495
40. Johnson-Leger C., and Imhof B.A. Forging the endothelium during inflammation: pushing at a half-open door?. Cell Tissue Res. 314 1 (2003) 93-105
41. Liu Y., et al. Regulation of leukocyte transmigration: cell surface interactions and signaling events. J. Immunol. 172 1 (2004) 7-13
42. Luscinskas F.W., et al. The role of endothelial cell lateral junctions during leukocyte trafficking. Immunol. Rev. 186 (2002) 57-67
43. Muller W.A. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 24 6 (2003) 327-334
44. Rao R.M., et al. Emerging topics in the regulation of leukocyte transendothelial migration. Microcirculation 12 1 (2005) 83-89
45. Huang M.T., et al. ICAM-2 mediates neutrophil transmigration in vivo: evidence for stimulus specificity and a role in PECAM-1-independent transmigration. Blood 107 12 (2006) 4721-4727
46. Salmi M., et al. CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 104 13 (2004) 3849-3857
47. Koskinen K., et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 103 9 (2004) 3388-3395
48. Salmi M., et al. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14 3 (2001) 265-276
49. Lalor P.F., et al. Recruitment of lymphocytes to the human liver. Immunol. Cell Biol. 80 1 (2002) 52-64
50. Wagner J.G., and Roth R.A. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol. Rev. 52 3 (2000) 349-374
51. Pober J.S., Kluger M.S., and Schechner J.S. Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin. Ann. N.Y. Acad. Sci. 941 (2001) 12-25
52. Shrikant P., and Mescher M.F. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162 5 (1999) 2858-2866
53. Hung K., et al. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 12 (1998) 2357-2368
54. Nagorsen D., et al. Natural T cell immunity against cancer. Clin. Cancer Res. 9 12 (2003) 4296-4303
55. Frey A.B., and Monu N. Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J. Leukoc. Biol. 79 4 (2006) 652-662
56. Poggi A., and Zocchi M.R. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch. Immunol. Ther. Exp. (Warsz) 54 5 (2006) 323-333
57. Schrier P.I., et al. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305 5937 (1983) 771-775
58. Gajewski T.F., et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213 (2006) 131-145
59. T.F. Gajewski, Y. Meng, H. Harlin, Immune suppression in the tumor microenvironment, J Immunother (1997), 2006. 29(3): p. 233-40.
60. Li B., et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12 22 (2006) 6808-6816
61. Kim R., Emi M., and Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119 2 (2006) 254-264
62. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 6 (2003) 685-693
63. Dirkx A.E., et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20 6 (2006) 621-630
64. Dirkx A.E., et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63 9 (2003) 2322-2329
65. Griffioen A.W., et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88 2 (1996) 667-673
66. Kim I., et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ. Res. 89 6 (2001) 477-479
67. Melder R.J., et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2 9 (1996) 992-997
68. Berger R., et al. Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J. Cutan. Pathol. 20 5 (1993) 399-406
69. Borgstrom P., et al. Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. J. Clin. Invest. 99 9 (1997) 2246-2253
70. Griffioen A.W., et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 56 5 (1996) 1111-1117
71. Kuzu I., et al. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab. Invest 69 3 (1993) 322-328
72. Nooijen P.T., et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am. J. Pathol. 152 3 (1998) 679-682
73. Peeters C.F., et al. Progressive loss of endothelial P-selectin expression with increasing malignancy in colorectal cancer. Lab. Invest 85 2 (2005) 248-256
74. Bessa X., et al. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology 122 4 (2002) 1122-1132
75. Fox S.B., et al. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J. Pathol. 177 4 (1995) 369-376
76. Berg E.L., et al. Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte traffic. Immunol. Rev. 108 (1989) 5-18
77. Briskin M., et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. 151 1 (1997) 97-110
78. De Keyser F., et al. The gut associated addressins: lymphocyte homing in the gut. Baillieres Clin. Rheumatol. 10 1 (1996) 25-39
79. Michl J., Qiu Q.Y., and Kuerer H.M. Homing receptors and addressins. Curr. Opin. Immunol. 3 3 (1991) 373-382
80. Shaw S.K., and Brenner M.B. The beta 7 integrins in mucosal homing and retention. Semin. Immunol. 7 5 (1995) 335-342
81. Salmi M., et al. Tumor endothelium selectively supports binding of IL-2-propagated tumor-infiltrating lymphocytes. J. Immunol. 154 11 (1995) 6002-6012
82. Onrust S.V., et al. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97 1 (1996) 54-64
83. Enarsson K., et al. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin. Immunol. 118 1 (2006) 24-34
84. Hellwig S.M., et al. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett. 120 2 (1997) 203-211
85. Chen S., et al. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J. Exp. Med. 202 12 (2005) 1679-1689
86. Curiel T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 9 (2004) 942-949
87. Zou W., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7 12 (2001) 1339-1346
88. Bono P., et al. Cloning and characterization of mouse vascular adhesion protein-1 reveals a novel molecule with enzymatic activity. J. Immunol. 160 11 (1998) 5563-5571
89. Bono P., et al. Isolation, structural characterization, and chromosomal mapping of the mouse vascular adhesion protein-1 gene and promoter. J. Immunol. 161 6 (1998) 2953-2960
90. Salmi M., and Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol. 22 4 (2001) 211-216
91. Salmi M., Tohka S., and Jalkanen S. Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear. Circ. Res. 86 12 (2000) 1245-1251
92. Smith D.J., et al. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J. Exp. Med. 188 1 (1998) 17-27
93. Forster-Horvath C., et al. Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma. Melanoma Res. 14 2 (2004) 135-140
94. Irjala H., et al. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J. Immunol. 166 11 (2001) 6937-6943
95. Yoong K.F., et al. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160 8 (1998) 3978-3988
96. DeGrendele H.C., et al. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J. Exp. Med. 183 3 (1996) 1119-1130
97. Griffioen A.W., et al. CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood 90 3 (1997) 1150-1159
98. Siegelman M.H., DeGrendele H.C., and Estess P. Activation and interaction of CD44 and hyaluronan in immunological systems. J. Leukoc. Biol. 66 2 (1999) 315-321
99. Toole B.P. Hyaluronan promotes the malignant phenotype. Glycobiology 12 3 (2002) 37R-42R
100. Toole B.P., and Hascall V.C. Hyaluronan and tumor growth. Am. J. Pathol. 161 3 (2002) 745-747
101. Rooney P., et al. The role of hyaluronan in tumour neovascularization (review). Int. J. Cancer 60 5 (1995) 632-636
102. Zhang H., and Issekutz A.C. Growth factor regulation of neutrophil-endothelial cell interactions. J. Leukoc. Biol. 70 2 (2001) 225-232
103. Kitayama J., et al. Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4(+) T-lymphocyte. Cancer Res. 54 17 (1994) 4729-4733
104. Tromp S.C., et al. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int. Immunol. 12 5 (2000) 671-676
105. Bouma-ter Steege J.C., et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin. Cancer Res. 10 21 (2004) 7171-7178
106. Piali L., et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181 2 (1995) 811-816
107. Zittermann S.I., and Issekutz A.C. Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J. Leukoc. Biol. 80 2 (2006) 247-257
108. Bouzin C., et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 178 3 (2007) 1505-1511
109. Allory Y., et al. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin. Cancer Res. 11 3 (2005) 1190-1197
110. Bussolati B., et al. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 17 9 (2003) 1159-1161
111. Bussolati B., et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp. Cell Res. 312 6 (2006) 913-924
112. Kaifi J.T., et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod. Pathol. 19 3 (2006) 399-406
113. Blaheta R.A., et al. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer 6 (2006) 294
114. Fogel M., et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 189 2 (2003) 237-247
115. Voura E.B., et al. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol. Biol. Cell 12 9 (2001) 2699-2710
116. Oliveira-Ferrer L., et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res. 64 24 (2004) 8932-8938
117. Tilki D., et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene 25 36 (2006) 4965-4974
118. Ergun S., et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol. Cell 5 2 (2000) 311-320
119. Wagener C., and Ergun S. Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp. Cell Res. 261 1 (2000) 19-24
120. Kilic N., et al. Pro-angiogenic signaling by the endothelial presence of CEACAM1. J. Biol. Chem. 280 3 (2005) 2361-2369
121. Skubitz K.M., Campbell K.D., and Skubitz A.P. Synthetic peptides of CD66a stimulate neutrophil adhesion to endothelial cells. J. Immunol. 164 8 (2000) 4257-4264
122. Nagaishi T., et al. Role of CEACAM1 as a regulator of T cells. Ann. N.Y. Acad. Sci. 1072 (2006) 155-175
123. Goerdt S., Bhardwaj R., and Sorg C. Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am. J. Pathol. 142 5 (1993) 1409-1422
124. Irjala H., et al. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63 15 (2003) 4671-4676
125. Kzhyshkowska J., Gratchev A., and Goerdt S. Stabilin-1, a homeostatic scavenger receptor with multiple functions. J. Cell Mol. Med. 10 3 (2006) 635-649
126. Prevo R., et al. Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor stabilin-1 (FEEL-1/CLEVER-1). J. Biol. Chem. 279 50 (2004) 52580-52592
127. Bixel M.G., Petri B., Khandoga A.G., Khandoga A., Wolburg-Buchholz K., Wolburg H., Marz S., Krombach F., and Vestweber D. CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood 109 (2007) 5327-5336
128. Griffioen A.W., and Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52 2 (2000) 237-268
129. Zhang H., and Issekutz A.C. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am. J. Pathol. 160 6 (2002) 2219-2230
130. Anastassiou G., et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma. Oncology 53 2 (1996) 127-132
131. Dworzak M.N., et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 83 2 (1994) 415-425
132. Gelin C., et al. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J. 8 11 (1989) 3253-3259
133. Kovar H., et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 5 7 (1990) 1067-1070
134. Schenkel A.R., et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat. Immunol. 3 2 (2002) 143-150
135. Salmi M., Koskinen K., Henttinen T., Elima K., and Jalkanen S. CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 104 (2004) 3849-3857
136. Lou O., et al. CD99 is a key mediator of the transendothelial migration of neutrophils. J. Immunol. 178 2 (2007) 1136-1143
137. Aurrand-Lions M., Johnson-Leger C., and Imhof B.A. The last molecular fortress in leukocyte trans-endothelial migration. Nat. Immunol. 3 2 (2002) 116-118
138. Ebnet K., et al. Junctional adhesion molecules (JAMs): more molecules with dual functions?. J. Cell Sci. 117 Pt 1 (2004) 19-29
139. Martin-Padura I., et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J. Cell Biol. 142 1 (1998) 117-127
140. Sobocka M.B., et al. Signaling pathways of the F11 receptor (F11R; a.k.a. JAM-1, JAM-A) in human platelets: F11R dimerization, phosphorylation and complex formation with the integrin GPIIIa. J. Recept. Signal Transduct. Res. 24 1-2 (2004) 85-105
141. Ludwig R.J., et al. Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J. Invest. Dermatol. 125 5 (2005) 969-976
142. Ostermann G., et al. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat. Immunol. 3 2 (2002) 151-158
143. Ebnet K., et al. The junctional adhesion molecule (JAM) family members JAM-2 and JAM-3 associate with the cell polarity protein PAR-3: a possible role for JAMs in endothelial cell polarity. J. Cell Sci. 116 Pt 19 (2003) 3879-3891
144. Zen K., et al. JAM-C is a component of desmosomes and a ligand for CD11b/CD18-mediated neutrophil transepithelial migration. Mol. Biol. Cell 15 8 (2004) 3926-3937
145. Fraemohs L., et al. The functional interaction of the beta 2 integrin lymphocyte function-associated antigen-1 with junctional adhesion molecule-A is mediated by the I domain. J. Immunol. 173 10 (2004) 6259-6264
146. Johnson-Leger C.A., et al. Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration. Blood 100 7 (2002) 2479-2486
147. Lamagna C., et al. Dual interaction of JAM-C with JAM-B and alpha(M)beta2 integrin: function in junctional complexes and leukocyte adhesion. Mol. Biol. Cell 16 10 (2005) 4992-5003
148. Santoso S., et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J. Exp. Med. 196 5 (2002) 679-691
149. Lamagna C., et al. Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res. 65 13 (2005) 5703-5710
150. Naik M.U., Vuppalanchi D., and Naik U.P. Essential role of junctional adhesion molecule-1 in basic fibroblast growth factor-induced endothelial cell migration. Arterioscler. Thromb. Vasc. Biol. 23 12 (2003) 2165-2171
151. Parise L.V. JAM-1 regulation of endothelial cell migration: implications for angiogenesis. Arterioscler. Thromb. Vasc. Biol. 23 12 (2003) 2119-2120
152. Dejana E., Spagnuolo R., and Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb. Haemost. 86 1 (2001) 308-315
153. Cooke V.G., Naik M.U., and Naik U.P. Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26 9 (2006) 2005-2011
154. Ozaki H., et al. Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. J. Immunol. 163 2 (1999) 553-557
155. Naik M.U., et al. Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood 102 6 (2003) 2108-2114
156. He J., and Baum L.G. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab. Invest 86 6 (2006) 578-590
157. Thijssen V.L., et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 103 43 (2006) 15975-15980
158. Gotsch U., et al. VE-cadherin antibody accelerates neutrophil recruitment in vivo. J. Cell Sci. 110 Pt 5 (1997) 583-588
159. Shaw S.K., et al. Real-time imaging of vascular endothelial-cadherin during leukocyte transmigration across endothelium. J. Immunol. 167 4 (2001) 2323-2330
160. Liao F., et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res. 60 24 (2000) 6805-6810
161. Ruoslahti E., and Pierschbacher M.D. Arg-Gly-Asp: a versatile cell recognition signal. Cell 44 4 (1986) 517-518
162. Benedetto S., et al. Quantification of the expression level of integrin receptor alpha(v)beta3 in cell lines and MR imaging with antibody-coated iron oxide particles. Magn. Reson. Med. 56 4 (2006) 711-716
163. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?. Eur. J. Nucl. Med. Mol. Imaging 33 Suppl. 1 (2006) 54-63
164. Haubner R.H., et al. Radiotracer-based strategies to image angiogenesis. Q. J. Nucl. Med. 47 3 (2003) 189-199
165. Janssen M.L., et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 62 21 (2002) 6146-6151
166. Lim E.H., et al. A review: integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine 1 2 (2005) 110-114
167. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol. Pharm. 3 5 (2006) 472-487
168. Mulder W.J., et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 19 14 (2005) 2008-2010
169. Mulder W.J., et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 21 2 (2007) 378-383
170. Geninatti Crich S., et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res. 66 18 (2006) 9196-9201
171. Yan X., et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102 1 (2003) 184-191
172. Boutry S., et al. Specific E-selectin targeting with a superparamagnetic MRI contrast agent. Contrast Media Mol. Imaging 1 1 (2006) 15-22
173. Mulder W.J., et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 15 4 (2004) 799-806
174. Sibson N.R., et al. MRI detection of early endothelial activation in brain inflammation. Magn. Reson. Med. 51 2 (2004) 248-252
175. Sadeghi M.M., et al. Vascular cell adhesion molecule-1-targeted detection of endothelial activation in human microvasculature. Transplant. Proc. 36 5 (2004) 1585-1591
176. Kelly K.A., et al. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96 3 (2005) 327-336
177. Nahrendorf M., et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114 14 (2006) 1504-1511
178. Jaakkola K., et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am. J. Pathol. 157 2 (2000) 463-471
179. Sipkins D.A., et al. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J. Neuroimmunol. 104 1 (2000) 1-9
180. Temming K., et al. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8 6 (2005) 381-402
181. Bequet-Romero M., et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 10 1 (2007) 23-34
182. Slager E.H., et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 107 12 (2006) 4954-4960
183. Wada S., et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 65 11 (2005) 4939-4946
184. Bu P., et al. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol. Cancer Ther. 5 11 (2006) 2872-2878
185. Mills L., et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 62 17 (2002) 5106-5114
186. Griffioen A.W., et al. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int. J. Cancer 80 2 (1999) 315-319
187. Luo J., et al. Angiostatin upregulates E-selectin in proliferating endothelial cells. Biochem. Biophys. Res. Commun. 245 3 (1998) 906-911
188. Hellebrekers D.M., et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 66 22 (2006) 10770-10777
189. Hellebrekers D.M., et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol. Cancer Ther. 5 2 (2006) 467-475
190. Cuadros C., et al. Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. Cancer Res. 63 18 (2003) 5895-5901
191. Gyorffy S., et al. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J. Immunol. 166 10 (2001) 6212-6217
192. Huang X., et al. Combined antiangiogenic and immune therapy of prostate cancer. Angiogenesis 8 1 (2005) 13-23
193. Nair S., et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102 3 (2003) 964-971
194. Yu Y., et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc. Natl. Acad. Sci. U. S. A. 101 21 (2004) 8005-8010
195. Hebbar M., et al. Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients. Clin. Cancer Res. 5 6 (1999) 1427-1433
196. Dosquet C., et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin. Cancer Res. 3 12 Pt 1 (1997) 2451-2458
197. Bewick M., et al. Evaluation of sICAM-1, sVCAM-1, and sE-Selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy. Stem Cells Dev. 13 3 (2004) 281-294
198. Hoffmann R., et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br. J. Cancer 79 11-12 (1999) 1742-1745
199. Kawano T., et al. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am. J. Otolaryngol. 26 5 (2005) 308-313
200. O'Hanlon D.M., et al. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur. J. Cancer 38 17 (2002) 2252-2257
201. Roselli M., et al. Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. Oncology 65 2 (2003) 132-138
202. Altomonte M., et al. Differential levels of soluble intercellular
203. Becker J.C., et al. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J. Immunol. 147 12 (1991) 4398-4401
204. Gho Y.S., et al. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res. 61 10 (2001) 4253-4257
205. Gho Y.S., Kleinman H.K., and Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. 59 20 (1999) 5128-5132
206. Koch A.E., et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376 6540 (1995) 517-519
207. Nguyen M., Strubel N.A., and Bischoff J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365 6443 (1993) 267-269
208. Ali A.A., et al. Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer. Eur. J. Surg. Oncol. 30 3 (2004) 292-295
209. Bromwich E.J., et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br. J. Cancer 89 10 (2003) 1906-1908
210. Canna K., et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br. J. Cancer 92 4 (2005) 651-654
211. Mantovani A., Allavena P., and Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur. J. Cancer 40 11 (2004) 1660-1667
212. Mantovani A., Schioppa T., Porta C., Allavena P., and Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25 (2006) 315-322
213. Treilleux I., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10 22 (2004) 7466-7474
214. Ito N., et al. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res. 25 3B (2005) 2027-2031
215. Mantovani A., et al. The origin and function of tumor-associated macrophages. Immunol. Today 13 7 (1992) 265-270
216. Mantovani A., Bussolino F., and Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 6 8 (1992) 2591-2599
217. Dirkx A.E., et al. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80 6 (2006) 1183-1196
218. Cho Y., et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 63 7 (2003) 1555-1559
219. Eerola A.K., Soini Y., and Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6 5 (2000) 1875-1881
220. Hiraoka K., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br. J. Cancer 94 2 (2006) 275-280
221. Menard S., et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin. Cancer Res. 3 5 (1997) 817-819
222. Oshikiri T., et al. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J. Surg. Oncol. 84 4 (2003) 224-228
223. Zhang L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 3 (2003) 203-213
224. Beyer M., and Schultze J.L. Regulatory T cells in cancer. Blood 108 3 (2006) 804-811
225. Lizee G., et al. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res. 12 16 (2006) 4794-4803
226. Ralainirina N., Poli A., Michel T., Poos L., Andres E., Hentges F., and Zimmer J. Control of NK cell functions by CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 81 (2006) 144-153
227. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev., Immunol. 6 4 (2006) 295-307
228. Dannull J., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115 12 (2005) 3623-3633
229. Sutmuller R.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 6 (2001) 823-832
230. Alves A., et al. Adjuvant interleukin-12 gene therapy for the management of colorectal liver metastases. Cancer Gene Ther. 11 12 (2004) 782-789
231. Klebanoff C.A., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 101 7 (2004) 1969-1974
232. Romano F., et al. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. Hepatogastroenterology 53 70 (2006) 634-638
233. Rubinstein M.P., et al. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J. Immunol. 169 9 (2002) 4928-4935
234. Ye C., et al. Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int. J. Cancer 61 4 (1995) 455-460
235. Klemke M., Weschenfelder T., Konstandin M.H., and Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J. Cell Physiol. 212 (2007) 368-374
236. Tachimori A., et al. Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma. Eur. J. Cancer 41 12 (2005) 1802-1810
237. Huang W.C., et al. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis 25 10 (2004) 1925-1934
238. Rosette C., et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26 5 (2005) 943-950
239. Natali P.G., et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57 8 (1997) 1554-1560
240. Lin Y.C., et al. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin. Cancer Res. 12 23 (2006) 7165-7173